AbbVie Inc.
As of Oct 22, 2026, AbbVie is in Stage 2, the uptrend phase, now in week 16 (since Jul 7, 2026). It closed at $285.19, 1.3% below its 52-week high and above its 200-day average, which is rising.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 9 in Drug Manufacturers - General · #1 of 272 in Health Care
Is ABBV early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
ABBV among Drug Manufacturers - General10th of 21 by relative strength
All 21 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | MRK | Stage 2 · wk 16 | 92 | −0.6% |
| 2 | BIIB | Stage 2 · wk 21 | 92 | +11.6% |
| 3 | LLY | Stage 2 · wk 1 | 90 | +13.5% |
| 4 | AMGN | Stage 2 · wk 16 | 87 | +10.1% |
| 5 | OGN | Stage 2 · wk 23 | 87 | +0.1% |
| 6 | BMY | Stage 3 · wk 1 | 85 | +4.1% |
| 7 | JNJ | Stage 2 · wk 16 | 83 | −0.6% |
| 8 | PFE | Stage 2 · wk 8 | 77 | +7.9% |
| …10 | ABBV | Stage 2 · wk 16 | 74 | +8.2% |
AbbVie: quick answers
What stage is AbbVie in?
As of Oct 22, 2026, AbbVie (ABBV) is in Stage 2, the uptrend phase. It entered Stage 2 on Jul 7, 2026 and is in week 16. What the four stages mean
Is AbbVie in an uptrend?
Yes. AbbVie is in a Stage 2 uptrend. It trades 22.9% above its 200-day average, which is rising.
How far is AbbVie from its 52-week high?
AbbVie closed at $285.19 on Oct 22, 2026, 1.3% below its 52-week high of $289.08. Its 52-week low is $194.79.
How has AbbVie performed over the past year?
As of Oct 22, 2026, AbbVie is up 26.9% over the past year and up 28.1% so far in 2026.
Which sector and industry is AbbVie in?
AbbVie is in the Drug Manufacturers - General industry, part of the Health Care sector.
About this companyHealth Care· Drug Manufacturers - General
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.